Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Athersys, Inc.    ATHX

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Athersys, Inc. : Analysis Reports On Active NASDAQ Stocks: (NASDAQ: ATHX), (NASDAQ: PDLI)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/18/2013 | 07:40am CET

New York (April 18th, 2013) - Athersys, Inc. (NASDAQ: ATHX) announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has approved Athersys' application to expand its ongoing Phase 2 study evaluating the administration of MultiStem(R) therapy to patients who have suffered an ischemic stroke. Enrollment at United Kingdom sites is expected to commence following final Ethics Committee review and the completion of final preparations at participating clinical centers.

"The MHRA authorization will enable us to bring several leading United Kingdom stroke centers into the study, which will help us to speed the completion of the stroke clinical trial," said Dr. Gil Van Bokkelen, Chairman and Chief Executive Officer of Athersys. "The authorization is also noteworthy as it marks the initiation of MultiStem clinical development activity in the United Kingdom."

Athersys, Inc, a biotechnology company, focuses on the research and development in the field of regenerative medicine.

Get everything traders and investors are looking for when trading ATHX here:

http://stockreportdaily.com/market-scan/?symbol=ATHX


PDL BioPharma Inc. (NASDAQ:PDLI) traded at $ 7.45 in the last session, which is 0.00 (0.00%). The stock has a Range of 7.31 - 7.46. The stock has a 52 week low and high of 6.09 - 8.43 respectively. The stock has a Market Cap of 1.04B. The stock traded a volume of 1.66M. The stock has a 30 day average volume of 1.81M.

In trading on Wednesday, shares of PDL BioPharmaInc (PDLI) crossed below their 200 day moving average of $7.32, changing hands as low as $7.31 per share.

PDL BioPharma, Inc. (PDL) is a biotech company. PDL is engaged in the management of antibody humanization patents and royalty assets, which consist of its Queen et al. patents and license agreements with various biotechnology and pharmaceutical companies. The Company receives royalties based on sales of humanized antibody products marketed and may also receive royalty payments on additional humanized antibody products launched before final expiry in December 2014.

Find out more on PDLI here:

http://stockreportdaily.com/market-scan/?symbol=PDLI

ABOUT US:

Stockreportdaily.com issues momentum alerts on stocks that can provide gains to day traders. Stockreportdaily.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more. Stockreportdaily.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Stockreportdaily.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the Stockreportdaily.com newsletter and receiving alerts from a Pro-Active team of researchers. Trading Alerts believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www. Stockreportdaily.com

Disclosure: Stockreportdaily.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit Stockreportdaily.com website, for complete risks and disclosures.

Investor Alley, its employees, officers, directors, shareholders and affiliates, hold no positions in the above-mentioned stocks.

For full disclaimer visit; http://www.Stockreportdaily.com/disclaimer/

Contact Info:
George Fitz
Stock Report Daily
info@Stockreportdaily.com
347-905-5009


© Accesswire 2013
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ATHERSYS, INC.
03/21 ATHERSYS : Two New Publications Highlight the Potential for MultiStem Treatment ..
03/20 Two New Publications Highlight the Potential for MultiStem® Treatment of Isch..
03/10 ATHERSYS : NEW MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND R..
03/09 Athersys Reports Financial Results for Fourth Quarter, Full Year 2016
03/09 ATHERSYS, INC / NEW : Results of Operations and Financial Condition, Financial S..
03/06ATHERSYS, INC. : annual earnings release
02/23 Overview of MultiStem® Clinical Trial in Japan Presentation at International ..
02/14 Athersys to Host Year-End 2016 Financial Results Call
02/01 Athersys Announces Closing of Public Offering of Common Stock
02/01 ATHERSYS, INC. (NASDAQ : ATHX) Files An 8-K Other Events
More news
Sector news : Bio Therapeutic Drugs
03/18DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 3rd Update
03/17DJAMGEN : Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- 2nd Update
03/17DJAMGEN : Money-Back Guarantee
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke -- Update
03/17DJAmgen's Repatha Study Shows Reduced Risk of Heart Attack, Stroke
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
03/09 Athersys' (ATHX) CEO Gil Van Bokkelen on Q4 2016 Results - Earnings Call Tran..
03/09 Athersys misses by $0.02, beats on revenue
03/08 Notable earnings after Thursday?s close
02/23 Athersys perks up ahead of MultiStem presentation at stroke meeting; shares a..
02/07 PREMARKET GAINERS / LOSERS AS OF 9 : 10 am
Advertisement
Financials ($)
Sales 2017 6,86 M
EBIT 2017 -29,0 M
Net income 2017 -26,5 M
Debt 2017 1,83 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 18,5x
Capi. / Sales 2018 78,7x
Capitalization 125 M
More Financials
Chart ATHERSYS, INC.
Duration : Period :
Athersys, Inc. Technical Analysis Chart | ATHX | US04744L1061 | 4-Traders
Full-screen chart
Technical analysis trends ATHERSYS, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 4
Average target price 7,00 $
Spread / Average Target 514%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Gil van Bokkelen Chairman & Chief Executive Officer
William B. J. Lehmann President, Chief Operating Officer & Secretary
Laura K. Campbell Chief Accounting Officer & Senior VP-Finance
John J. Harrington Director, Chief Scientific Officer & Executive VP
Jordan S. Davis Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ATHERSYS, INC.-25.49%125
AMGEN, INC.14.53%123 319
CELGENE CORPORATION6.58%95 978
GILEAD SCIENCES, INC.-5.28%88 658
REGENERON PHARMACEUTIC..0.56%39 159
ACTELION LTD24.49%29 874
More Results